pharma
-
The power of patient voice in clinical trial design
The increased patient-centric focus in drug development by the FDA is highly encouraging and expected to become more mainstream and legislated.
-
Artificial Intelligence, Pharma
Report: IBM is ending sales of Watson for Drug Discovery
IBM is stopping the development and sales of the product, which uses Watson AI to help pharmaceutical companies find new drugs, because it wasn’t yielding large enough financial returns, according to a STAT report.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Why pharma is starting to think more like Amazon
As pharma continues to close the gap between the operational and analytical needs of their business, they can look to other industries for best practices.
-
Five innovation trends that will impact the healthcare industry in 2019
The behavioral health epidemic, artificial intelligence and more procedures being done in outpatient settings are some the key 2019 trends that will determine how decision makers purchase technology.
-
MedCity Influencers, BioPharma
Biopharma needs a new R&D, innovation model
Strategic partnerships are one way for biopharmaceutical companies to expand capabilities and offerings and proactively define their future versus having it defined for them.
-
What do CMIOs think of medication management initiatives?
A new survey found chief medical information officers believe medication management improvement initiatives have positively impacted patient safety, but factors like workflow variation and a lack of price transparency still compromise patients’ well-being.
-
Pharma is making inroads into digital health, albeit slowly
Panelists highlight Roche’s acquisition of Flatiron Health in February and use of AI/ML in drug development.
-
The potential for conflict of interest when health policy experts also serve on the boards of pharma companies
The issue of conflicts of interest has become more pressing in recent years as drug prices soar and healthcare companies reach out to the academic and policy community for advice — often with generous payments attached, ethics experts say.
-
Roche acquires the rest of Foundation Medicine for $2.4B, supporting its precision medicine strategy
It’s the latest in a series of companies Roche has acquired to add services and technology to the Big Pharma’s drug development business, particularly in cancer treatment.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
FDA: Drugmaker ‘shenanigans’ delaying cheaper competitors and boosting prices
A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.
-
Drugmakers increasingly target “baskets” of tumors based on mutations
A new report shows a steady growth in so-called “basket studies” in oncology, along with growing interest by the drug industry.
-
Trump’s drug cost cutting plans include transparency, but critics doubt much will change
In his plans to cut sky-high drug prices unveiled Friday, Trump said that increasing industry competition will help Americans save at the pharmacy counter.
-
Martin Shkreli’s in prison but Daraprim prices are still high
Shkreli, 35, is serving a seven-year prison term for securities fraud (unrelated to Daraprim). Turing has renamed itself Vyera Pharmaceuticals. But Daraprim, which costs pennies to make and is used to treat the parasitic infection toxoplasmosis still retails for more than $750 per pill, according to drug website GoodRx.com.
-
A look at how one pharma company responded to the pressure on drug prices: Ramping up political activity
The pharma industry as a whole has cranked up political contributions and lobbying. Meanwhile, despite much talk about change, Congress and the Trump administration have done little to control drug prices or threaten drug-company profits.
-
FDA’s Scott Gottlieb highlights digital health initiatives from new incubator to AI at Health Datapalooza
At the ninth annual Health Datapalooza conference in Washington D.C. this week, Scott Gottlieb also provided an update on the pre-certification program, which is scheduled to launch before the end of the year.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
